nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.177	1	CbGbCtD
Valproic Acid—UGT1A8—tongue—amyotrophic lateral sclerosis	0.014	0.0989	CbGeAlD
Valproic Acid—Gastrointestinal tract irritation—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0214	CcSEcCtD
Valproic Acid—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.00971	0.0205	CcSEcCtD
Valproic Acid—CNS depression NOS—Riluzole—amyotrophic lateral sclerosis	0.00882	0.0186	CcSEcCtD
Valproic Acid—Dementia—Riluzole—amyotrophic lateral sclerosis	0.00882	0.0186	CcSEcCtD
Valproic Acid—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00851	0.018	CcSEcCtD
Valproic Acid—Personality disorder—Riluzole—amyotrophic lateral sclerosis	0.00836	0.0177	CcSEcCtD
Valproic Acid—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00738	0.0156	CcSEcCtD
Valproic Acid—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.00717	0.0151	CcSEcCtD
Valproic Acid—ALDH5A1—hindbrain—amyotrophic lateral sclerosis	0.00698	0.0493	CbGeAlD
Valproic Acid—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00653	0.0138	CcSEcCtD
Valproic Acid—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00645	0.0136	CcSEcCtD
Valproic Acid—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00645	0.0136	CcSEcCtD
Valproic Acid—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00645	0.0136	CcSEcCtD
Valproic Acid—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00637	0.0135	CcSEcCtD
Valproic Acid—ABAT—hindbrain—amyotrophic lateral sclerosis	0.00597	0.0422	CbGeAlD
Valproic Acid—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00595	0.0126	CcSEcCtD
Valproic Acid—HDAC2—tongue—amyotrophic lateral sclerosis	0.00587	0.0415	CbGeAlD
Valproic Acid—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00575	0.0121	CcSEcCtD
Valproic Acid—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00558	0.0118	CcSEcCtD
Valproic Acid—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00541	0.0114	CcSEcCtD
Valproic Acid—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00536	0.0113	CcSEcCtD
Valproic Acid—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00531	0.0112	CcSEcCtD
Valproic Acid—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00521	0.011	CcSEcCtD
Valproic Acid—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00506	0.0107	CcSEcCtD
Valproic Acid—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00484	0.0102	CcSEcCtD
Valproic Acid—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.0048	0.0101	CcSEcCtD
Valproic Acid—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00472	0.00997	CcSEcCtD
Valproic Acid—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00468	0.00989	CcSEcCtD
Valproic Acid—HDAC2—hindbrain—amyotrophic lateral sclerosis	0.0045	0.0318	CbGeAlD
Valproic Acid—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.0044	0.00928	CcSEcCtD
Valproic Acid—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00921	CcSEcCtD
Valproic Acid—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.0043	0.00908	CcSEcCtD
Valproic Acid—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00412	0.00869	CcSEcCtD
Valproic Acid—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00863	CcSEcCtD
Valproic Acid—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00851	CcSEcCtD
Valproic Acid—ALDH5A1—brainstem—amyotrophic lateral sclerosis	0.004	0.0283	CbGeAlD
Valproic Acid—OGDH—medulla oblongata—amyotrophic lateral sclerosis	0.00399	0.0282	CbGeAlD
Valproic Acid—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00398	0.0084	CcSEcCtD
Valproic Acid—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00395	0.00834	CcSEcCtD
Valproic Acid—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00395	0.00834	CcSEcCtD
Valproic Acid—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00392	0.00829	CcSEcCtD
Valproic Acid—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00382	0.00807	CcSEcCtD
Valproic Acid—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00371	0.00782	CcSEcCtD
Valproic Acid—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00368	0.00778	CcSEcCtD
Valproic Acid—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00366	0.00773	CcSEcCtD
Valproic Acid—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00764	CcSEcCtD
Valproic Acid—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.0036	0.00759	CcSEcCtD
Valproic Acid—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00357	0.00755	CcSEcCtD
Valproic Acid—OGDH—spinal cord—amyotrophic lateral sclerosis	0.00356	0.0251	CbGeAlD
Valproic Acid—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00737	CcSEcCtD
Valproic Acid—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00737	CcSEcCtD
Valproic Acid—ABAT—brainstem—amyotrophic lateral sclerosis	0.00342	0.0242	CbGeAlD
Valproic Acid—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00717	CcSEcCtD
Valproic Acid—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00717	CcSEcCtD
Valproic Acid—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00332	0.00702	CcSEcCtD
Valproic Acid—Coma—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00698	CcSEcCtD
Valproic Acid—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00327	0.0069	CcSEcCtD
Valproic Acid—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00327	0.0069	CcSEcCtD
Valproic Acid—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00669	CcSEcCtD
Valproic Acid—ACADSB—medulla oblongata—amyotrophic lateral sclerosis	0.00317	0.0224	CbGeAlD
Valproic Acid—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00663	CcSEcCtD
Valproic Acid—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00656	CcSEcCtD
Valproic Acid—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00308	0.0065	CcSEcCtD
Valproic Acid—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.003	0.00634	CcSEcCtD
Valproic Acid—OGDH—nervous system—amyotrophic lateral sclerosis	0.003	0.0212	CbGeAlD
Valproic Acid—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00299	0.00631	CcSEcCtD
Valproic Acid—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0062	CcSEcCtD
Valproic Acid—OGDH—central nervous system—amyotrophic lateral sclerosis	0.00289	0.0204	CbGeAlD
Valproic Acid—Injury—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00603	CcSEcCtD
Valproic Acid—ACADSB—spinal cord—amyotrophic lateral sclerosis	0.00283	0.02	CbGeAlD
Valproic Acid—OGDH—cerebellum—amyotrophic lateral sclerosis	0.00282	0.0199	CbGeAlD
Valproic Acid—HDAC2—embryo—amyotrophic lateral sclerosis	0.00281	0.0199	CbGeAlD
Valproic Acid—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0059	CcSEcCtD
Valproic Acid—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0059	CcSEcCtD
Valproic Acid—ALDH5A1—medulla oblongata—amyotrophic lateral sclerosis	0.00279	0.0197	CbGeAlD
Valproic Acid—HDAC9—nervous system—amyotrophic lateral sclerosis	0.00264	0.0187	CbGeAlD
Valproic Acid—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00264	0.00557	CcSEcCtD
Valproic Acid—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00554	CcSEcCtD
Valproic Acid—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00554	CcSEcCtD
Valproic Acid—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00546	CcSEcCtD
Valproic Acid—HDAC2—brainstem—amyotrophic lateral sclerosis	0.00258	0.0182	CbGeAlD
Valproic Acid—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00541	CcSEcCtD
Valproic Acid—HDAC9—central nervous system—amyotrophic lateral sclerosis	0.00254	0.018	CbGeAlD
Valproic Acid—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00535	CcSEcCtD
Valproic Acid—ALDH5A1—spinal cord—amyotrophic lateral sclerosis	0.00249	0.0176	CbGeAlD
Valproic Acid—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00525	CcSEcCtD
Valproic Acid—HDAC9—cerebellum—amyotrophic lateral sclerosis	0.00249	0.0176	CbGeAlD
Valproic Acid—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00521	CcSEcCtD
Valproic Acid—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00506	CcSEcCtD
Valproic Acid—ABAT—medulla oblongata—amyotrophic lateral sclerosis	0.00239	0.0169	CbGeAlD
Valproic Acid—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00501	CcSEcCtD
Valproic Acid—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00499	CcSEcCtD
Valproic Acid—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00489	CcSEcCtD
Valproic Acid—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00489	CcSEcCtD
Valproic Acid—OGDH—brain—amyotrophic lateral sclerosis	0.00229	0.0162	CbGeAlD
Valproic Acid—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00479	CcSEcCtD
Valproic Acid—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00479	CcSEcCtD
Valproic Acid—ACADSB—cerebellum—amyotrophic lateral sclerosis	0.00224	0.0158	CbGeAlD
Valproic Acid—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00222	0.0047	CcSEcCtD
Valproic Acid—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00461	CcSEcCtD
Valproic Acid—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00459	CcSEcCtD
Valproic Acid—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00455	CcSEcCtD
Valproic Acid—ABAT—spinal cord—amyotrophic lateral sclerosis	0.00213	0.015	CbGeAlD
Valproic Acid—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00448	CcSEcCtD
Valproic Acid—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00448	CcSEcCtD
Valproic Acid—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00443	CcSEcCtD
Valproic Acid—ALDH5A1—nervous system—amyotrophic lateral sclerosis	0.0021	0.0148	CbGeAlD
Valproic Acid—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00437	CcSEcCtD
Valproic Acid—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00436	CcSEcCtD
Valproic Acid—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00433	CcSEcCtD
Valproic Acid—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00204	0.0043	CcSEcCtD
Valproic Acid—HDAC9—brain—amyotrophic lateral sclerosis	0.00202	0.0143	CbGeAlD
Valproic Acid—ALDH5A1—central nervous system—amyotrophic lateral sclerosis	0.00202	0.0143	CbGeAlD
Valproic Acid—Depression—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00426	CcSEcCtD
Valproic Acid—ALDH5A1—cerebellum—amyotrophic lateral sclerosis	0.00197	0.0139	CbGeAlD
Valproic Acid—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00416	CcSEcCtD
Valproic Acid—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00415	CcSEcCtD
Valproic Acid—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00194	0.0041	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00404	CcSEcCtD
Valproic Acid—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00403	CcSEcCtD
Valproic Acid—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00401	CcSEcCtD
Valproic Acid—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00399	CcSEcCtD
Valproic Acid—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00185	0.0039	CcSEcCtD
Valproic Acid—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00385	CcSEcCtD
Valproic Acid—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00384	CcSEcCtD
Valproic Acid—ACADSB—brain—amyotrophic lateral sclerosis	0.00182	0.0129	CbGeAlD
Valproic Acid—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00383	CcSEcCtD
Valproic Acid—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00382	CcSEcCtD
Valproic Acid—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00382	CcSEcCtD
Valproic Acid—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00381	CcSEcCtD
Valproic Acid—HDAC2—medulla oblongata—amyotrophic lateral sclerosis	0.0018	0.0127	CbGeAlD
Valproic Acid—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00379	CcSEcCtD
Valproic Acid—ABAT—nervous system—amyotrophic lateral sclerosis	0.00179	0.0127	CbGeAlD
Valproic Acid—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00378	CcSEcCtD
Valproic Acid—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00377	CcSEcCtD
Valproic Acid—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00376	CcSEcCtD
Valproic Acid—ABAT—central nervous system—amyotrophic lateral sclerosis	0.00173	0.0122	CbGeAlD
Valproic Acid—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00363	CcSEcCtD
Valproic Acid—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00358	CcSEcCtD
Valproic Acid—ABAT—cerebellum—amyotrophic lateral sclerosis	0.00169	0.0119	CbGeAlD
Valproic Acid—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00348	CcSEcCtD
Valproic Acid—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00346	CcSEcCtD
Valproic Acid—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00346	CcSEcCtD
Valproic Acid—Chills—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00344	CcSEcCtD
Valproic Acid—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00343	CcSEcCtD
Valproic Acid—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00339	CcSEcCtD
Valproic Acid—ALDH5A1—brain—amyotrophic lateral sclerosis	0.0016	0.0113	CbGeAlD
Valproic Acid—SLC16A1—medulla oblongata—amyotrophic lateral sclerosis	0.0016	0.0113	CbGeAlD
Valproic Acid—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00336	CcSEcCtD
Valproic Acid—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00334	CcSEcCtD
Valproic Acid—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00329	CcSEcCtD
Valproic Acid—Tension—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00328	CcSEcCtD
Valproic Acid—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00327	CcSEcCtD
Valproic Acid—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00324	CcSEcCtD
Valproic Acid—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00323	CcSEcCtD
Valproic Acid—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00321	CcSEcCtD
Valproic Acid—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00313	CcSEcCtD
Valproic Acid—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0031	CcSEcCtD
Valproic Acid—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00309	CcSEcCtD
Valproic Acid—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00307	CcSEcCtD
Valproic Acid—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00305	CcSEcCtD
Valproic Acid—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00301	CcSEcCtD
Valproic Acid—SLC16A1—spinal cord—amyotrophic lateral sclerosis	0.00142	0.0101	CbGeAlD
Valproic Acid—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00142	0.003	CcSEcCtD
Valproic Acid—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00299	CcSEcCtD
Valproic Acid—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00295	CcSEcCtD
Valproic Acid—Cough—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00291	CcSEcCtD
Valproic Acid—ABAT—brain—amyotrophic lateral sclerosis	0.00137	0.00968	CbGeAlD
Valproic Acid—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00288	CcSEcCtD
Valproic Acid—HDAC2—nervous system—amyotrophic lateral sclerosis	0.00135	0.00954	CbGeAlD
Valproic Acid—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00284	CcSEcCtD
Valproic Acid—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00284	CcSEcCtD
Valproic Acid—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00284	CcSEcCtD
Valproic Acid—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00283	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00282	CcSEcCtD
Valproic Acid—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00281	CcSEcCtD
Valproic Acid—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00278	CcSEcCtD
Valproic Acid—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00275	CcSEcCtD
Valproic Acid—HDAC2—central nervous system—amyotrophic lateral sclerosis	0.0013	0.00919	CbGeAlD
Valproic Acid—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00272	CcSEcCtD
Valproic Acid—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00272	CcSEcCtD
Valproic Acid—Infection—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00271	CcSEcCtD
Valproic Acid—HDAC2—cerebellum—amyotrophic lateral sclerosis	0.00127	0.00898	CbGeAlD
Valproic Acid—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00267	CcSEcCtD
Valproic Acid—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00267	CcSEcCtD
Valproic Acid—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00266	CcSEcCtD
Valproic Acid—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00265	CcSEcCtD
Valproic Acid—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00263	CcSEcCtD
Valproic Acid—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0026	CcSEcCtD
Valproic Acid—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00255	CcSEcCtD
Valproic Acid—SLC16A1—nervous system—amyotrophic lateral sclerosis	0.0012	0.00848	CbGeAlD
Valproic Acid—SLC22A7—brain—amyotrophic lateral sclerosis	0.0012	0.00848	CbGeAlD
Valproic Acid—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00248	CcSEcCtD
Valproic Acid—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00246	CcSEcCtD
Valproic Acid—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00245	CcSEcCtD
Valproic Acid—SLC22A6—brain—amyotrophic lateral sclerosis	0.00116	0.00818	CbGeAlD
Valproic Acid—SLC16A1—central nervous system—amyotrophic lateral sclerosis	0.00116	0.00816	CbGeAlD
Valproic Acid—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00243	CcSEcCtD
Valproic Acid—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00242	CcSEcCtD
Valproic Acid—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0024	CcSEcCtD
Valproic Acid—SLC16A1—cerebellum—amyotrophic lateral sclerosis	0.00113	0.00798	CbGeAlD
Valproic Acid—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00237	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00235	CcSEcCtD
Valproic Acid—CYP2A6—cerebellum—amyotrophic lateral sclerosis	0.00111	0.00786	CbGeAlD
Valproic Acid—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00235	CcSEcCtD
Valproic Acid—Pain—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00233	CcSEcCtD
Valproic Acid—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00233	CcSEcCtD
Valproic Acid—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00225	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00223	CcSEcCtD
Valproic Acid—HDAC2—brain—amyotrophic lateral sclerosis	0.00103	0.00729	CbGeAlD
Valproic Acid—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00216	CcSEcCtD
Valproic Acid—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00215	CcSEcCtD
Valproic Acid—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00215	CcSEcCtD
Valproic Acid—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000951	0.00201	CcSEcCtD
Valproic Acid—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000926	0.00195	CcSEcCtD
Valproic Acid—SLC16A1—brain—amyotrophic lateral sclerosis	0.000917	0.00648	CbGeAlD
Valproic Acid—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000913	0.00193	CcSEcCtD
Valproic Acid—SLC22A5—medulla oblongata—amyotrophic lateral sclerosis	0.000913	0.00645	CbGeAlD
Valproic Acid—SLC22A8—nervous system—amyotrophic lateral sclerosis	0.000907	0.00641	CbGeAlD
Valproic Acid—CYP2A6—brain—amyotrophic lateral sclerosis	0.000904	0.00639	CbGeAlD
Valproic Acid—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000883	0.00186	CcSEcCtD
Valproic Acid—SLC22A8—central nervous system—amyotrophic lateral sclerosis	0.000873	0.00617	CbGeAlD
Valproic Acid—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000853	0.0018	CcSEcCtD
Valproic Acid—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00082	0.00173	CcSEcCtD
Valproic Acid—SLC22A5—spinal cord—amyotrophic lateral sclerosis	0.000814	0.00575	CbGeAlD
Valproic Acid—Rash—Riluzole—amyotrophic lateral sclerosis	0.000814	0.00172	CcSEcCtD
Valproic Acid—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000813	0.00172	CcSEcCtD
Valproic Acid—Headache—Riluzole—amyotrophic lateral sclerosis	0.000808	0.00171	CcSEcCtD
Valproic Acid—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000767	0.00162	CcSEcCtD
Valproic Acid—SLC22A8—brain—amyotrophic lateral sclerosis	0.000693	0.0049	CbGeAlD
Valproic Acid—SLC22A5—cerebellum—amyotrophic lateral sclerosis	0.000645	0.00456	CbGeAlD
Valproic Acid—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000639	0.00451	CbGeAlD
Valproic Acid—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000595	0.00421	CbGeAlD
Valproic Acid—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000573	0.00405	CbGeAlD
Valproic Acid—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000538	0.0038	CbGeAlD
Valproic Acid—SLC22A5—brain—amyotrophic lateral sclerosis	0.000524	0.0037	CbGeAlD
Valproic Acid—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000518	0.00366	CbGeAlD
Valproic Acid—CYP2C8—brain—amyotrophic lateral sclerosis	0.000507	0.00359	CbGeAlD
Valproic Acid—CYP2B6—brain—amyotrophic lateral sclerosis	0.000455	0.00322	CbGeAlD
Valproic Acid—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00045	0.00318	CbGeAlD
Valproic Acid—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000433	0.00306	CbGeAlD
Valproic Acid—PTGS1—brain—amyotrophic lateral sclerosis	0.000411	0.00291	CbGeAlD
Valproic Acid—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	0.000108	0.000521	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000108	0.000521	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000107	0.000517	CbGpPWpGaD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000106	0.000512	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000105	0.000508	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000105	0.000503	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000104	0.000502	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000104	0.000499	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000104	0.000499	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000103	0.000497	CbGpPWpGaD
Valproic Acid—HDAC2—Factors involved in megakaryocyte development and platelet production—TP53—amyotrophic lateral sclerosis	0.000103	0.000496	CbGpPWpGaD
Valproic Acid—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000103	0.000495	CbGpPWpGaD
Valproic Acid—ACADSB—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.000102	0.00049	CbGpPWpGaD
Valproic Acid—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000101	0.000488	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000101	0.000485	CbGpPWpGaD
Valproic Acid—HDAC2—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	0.000101	0.000485	CbGpPWpGaD
Valproic Acid—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.95e-05	0.000479	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—APOE—amyotrophic lateral sclerosis	9.87e-05	0.000475	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	9.83e-05	0.000473	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.8e-05	0.000472	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	9.75e-05	0.000469	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.73e-05	0.000468	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	9.69e-05	0.000466	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—CHAT—amyotrophic lateral sclerosis	9.64e-05	0.000464	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—GSR—amyotrophic lateral sclerosis	9.57e-05	0.000461	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.48e-05	0.000456	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—GSR—amyotrophic lateral sclerosis	9.31e-05	0.000448	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	9.3e-05	0.000448	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	9.3e-05	0.000448	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—FIG4—amyotrophic lateral sclerosis	9.22e-05	0.000444	CbGpPWpGaD
Valproic Acid—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.17e-05	0.000442	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	9.15e-05	0.00044	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	9.09e-05	0.000438	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	9.09e-05	0.000438	CbGpPWpGaD
Valproic Acid—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.05e-05	0.000436	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.02e-05	0.000434	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—CHAT—amyotrophic lateral sclerosis	8.99e-05	0.000433	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.93e-05	0.00043	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—CST3—amyotrophic lateral sclerosis	8.89e-05	0.000428	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	8.87e-05	0.000427	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	8.82e-05	0.000424	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.67e-05	0.000417	CbGpPWpGaD
Valproic Acid—OGDH—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.65e-05	0.000417	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.65e-05	0.000416	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	8.51e-05	0.00041	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.4e-05	0.000404	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	8.4e-05	0.000404	CbGpPWpGaD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	8.38e-05	0.000403	CbGpPWpGaD
Valproic Acid—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.37e-05	0.000403	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—DAO—amyotrophic lateral sclerosis	8.34e-05	0.000401	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	8.32e-05	0.0004	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.29e-05	0.000399	CbGpPWpGaD
Valproic Acid—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.25e-05	0.000397	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	8.2e-05	0.000395	CbGpPWpGaD
Valproic Acid—SLC16A1—Hemostasis—IGF1—amyotrophic lateral sclerosis	7.98e-05	0.000384	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.91e-05	0.000381	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.89e-05	0.00038	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	7.88e-05	0.000379	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	7.88e-05	0.000379	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—CHAT—amyotrophic lateral sclerosis	7.86e-05	0.000378	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—APOE—amyotrophic lateral sclerosis	7.8e-05	0.000376	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.73e-05	0.000372	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—CHAT—amyotrophic lateral sclerosis	7.64e-05	0.000368	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	7.56e-05	0.000364	CbGpPWpGaD
Valproic Acid—HDAC2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	7.54e-05	0.000363	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.53e-05	0.000362	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.46e-05	0.000359	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	7.44e-05	0.000358	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.42e-05	0.000357	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.37e-05	0.000355	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.34e-05	0.000354	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—IGF1—amyotrophic lateral sclerosis	7.3e-05	0.000351	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	7.27e-05	0.00035	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	7.2e-05	0.000347	CbGpPWpGaD
Valproic Acid—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	7.15e-05	0.000344	CbGpPWpGaD
Valproic Acid—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	7.05e-05	0.000339	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	7.03e-05	0.000338	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	7.03e-05	0.000338	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.92e-05	0.000333	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.91e-05	0.000333	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.89e-05	0.000332	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—APOE—amyotrophic lateral sclerosis	6.82e-05	0.000328	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—PTGS2—amyotrophic lateral sclerosis	6.76e-05	0.000325	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.74e-05	0.000324	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	6.73e-05	0.000324	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.7e-05	0.000322	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	6.68e-05	0.000322	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	6.57e-05	0.000316	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.56e-05	0.000316	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—CASP9—amyotrophic lateral sclerosis	6.46e-05	0.000311	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	6.43e-05	0.00031	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	6.41e-05	0.000309	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	6.41e-05	0.000309	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PLB1—amyotrophic lateral sclerosis	6.32e-05	0.000304	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	6.3e-05	0.000303	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	6.21e-05	0.000299	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	6.17e-05	0.000297	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.98e-05	0.000288	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.98e-05	0.000288	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	5.86e-05	0.000282	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—GSR—amyotrophic lateral sclerosis	5.83e-05	0.000281	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.81e-05	0.00028	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.71e-05	0.000275	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	5.69e-05	0.000274	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—APOE—amyotrophic lateral sclerosis	5.69e-05	0.000274	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.67e-05	0.000273	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	5.62e-05	0.000271	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.62e-05	0.00027	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—ERBB4—amyotrophic lateral sclerosis	5.53e-05	0.000266	CbGpPWpGaD
Valproic Acid—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.52e-05	0.000266	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.48e-05	0.000264	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.48e-05	0.000264	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.45e-05	0.000262	CbGpPWpGaD
Valproic Acid—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.44e-05	0.000262	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.35e-05	0.000257	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.34e-05	0.000257	CbGpPWpGaD
Valproic Acid—SLC16A1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	5.21e-05	0.000251	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.18e-05	0.000249	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	5.12e-05	0.000247	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.11e-05	0.000246	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.1e-05	0.000245	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	5.08e-05	0.000245	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.06e-05	0.000244	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.06e-05	0.000244	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	5.01e-05	0.000241	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	4.98e-05	0.00024	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.83e-05	0.000233	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—CHAT—amyotrophic lateral sclerosis	4.79e-05	0.00023	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.77e-05	0.00023	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.76e-05	0.000229	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.75e-05	0.000229	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	4.7e-05	0.000226	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.67e-05	0.000225	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.66e-05	0.000224	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	4.63e-05	0.000223	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.62e-05	0.000222	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	4.6e-05	0.000221	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.52e-05	0.000218	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.44e-05	0.000214	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.39e-05	0.000212	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.39e-05	0.000212	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.38e-05	0.000211	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	4.32e-05	0.000208	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—APOE—amyotrophic lateral sclerosis	4.28e-05	0.000206	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	4.23e-05	0.000203	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	4.23e-05	0.000203	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.22e-05	0.000203	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.15e-05	0.0002	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.11e-05	0.000198	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	3.98e-05	0.000192	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.96e-05	0.000191	CbGpPWpGaD
Valproic Acid—SLC16A1—Hemostasis—TP53—amyotrophic lateral sclerosis	3.94e-05	0.00019	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—APOE—amyotrophic lateral sclerosis	3.92e-05	0.000189	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.9e-05	0.000188	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.88e-05	0.000187	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.88e-05	0.000187	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.87e-05	0.000186	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	3.87e-05	0.000186	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	3.86e-05	0.000186	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	3.85e-05	0.000185	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	3.78e-05	0.000182	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.78e-05	0.000182	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.73e-05	0.000179	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—APOE—amyotrophic lateral sclerosis	3.65e-05	0.000176	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.64e-05	0.000175	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.63e-05	0.000175	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—TP53—amyotrophic lateral sclerosis	3.6e-05	0.000173	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.59e-05	0.000173	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	3.56e-05	0.000171	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	3.51e-05	0.000169	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	3.38e-05	0.000163	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.34e-05	0.000161	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	3.27e-05	0.000157	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	3.24e-05	0.000156	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.24e-05	0.000156	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.22e-05	0.000155	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—APOE—amyotrophic lateral sclerosis	3.19e-05	0.000154	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.17e-05	0.000152	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—APOE—amyotrophic lateral sclerosis	3.11e-05	0.00015	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.07e-05	0.000148	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	3.06e-05	0.000147	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.01e-05	0.000145	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	3e-05	0.000144	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3e-05	0.000144	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.98e-05	0.000144	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.95e-05	0.000142	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—PTGS2—amyotrophic lateral sclerosis	2.93e-05	0.000141	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	2.92e-05	0.000141	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.82e-05	0.000136	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.77e-05	0.000133	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.72e-05	0.000131	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.68e-05	0.000129	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.66e-05	0.000128	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	2.66e-05	0.000128	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.57e-05	0.000124	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	2.52e-05	0.000121	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.52e-05	0.000121	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.5e-05	0.00012	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.5e-05	0.00012	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.48e-05	0.000119	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.43e-05	0.000117	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.36e-05	0.000114	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	2.32e-05	0.000112	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.27e-05	0.000109	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.19e-05	0.000105	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	2.14e-05	0.000103	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.13e-05	0.000102	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.08e-05	9.99e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.08e-05	9.99e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	2.06e-05	9.9e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.04e-05	9.84e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.03e-05	9.77e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—APOE—amyotrophic lateral sclerosis	1.95e-05	9.37e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.91e-05	9.18e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.91e-05	9.17e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.87e-05	8.98e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.83e-05	8.79e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.8e-05	8.67e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.76e-05	8.46e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.76e-05	8.45e-05	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.73e-05	8.32e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.66e-05	8.01e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.62e-05	7.78e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.62e-05	7.78e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	1.57e-05	7.56e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.57e-05	7.55e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	1.53e-05	7.39e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.44e-05	6.94e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.43e-05	6.89e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.42e-05	6.85e-05	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.41e-05	6.79e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.33e-05	6.42e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	1.33e-05	6.4e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.31e-05	6.33e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.22e-05	5.88e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.22e-05	5.88e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	1.19e-05	5.71e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.12e-05	5.41e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.08e-05	5.21e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.08e-05	5.18e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.05e-05	5.06e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.44e-06	4.54e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	9.24e-06	4.45e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.11e-06	4.38e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.67e-06	4.17e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.13e-06	3.91e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.41e-06	3.57e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	7.13e-06	3.43e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.33e-06	3.05e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.89e-06	2.35e-05	CbGpPWpGaD
